Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

TA161 Osteoporosis - secondary prevention including strontium ranelate: review decision - March 2014 information

TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014 (PDF 309 KB)

TA161 Osteoporosis - secondary prevention including strontium ranelate: review proposal - August 2013 information

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix A - provisional matrix of stakeholders (PDF 102 KB)

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 1.02 MB)

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix C - Decision Support Unit Report (PDF 560 KB)

TA161 Osteoporosis - secondary prevention including strontium ranelate: review update - August 2012 information

TA161 Osteoporosis - secondary prevention including strontium ranelate: review update - July 2010 information

Osteoporosis - secondary prevention including strontium ranelate: final appeal panel decision (PDF 42 KB)

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination 3 information

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination document (PDF 376 KB)

Osteoporosis - secondary prevention including strontium ranelate: Court Order, Memorandum of Understanding, background information and matrix of stakeholders for this reconsideration

Osteoporosis - secondary prevention including strontium ranelate: Court Order and Memorandum of Understanding (PDF 367 KB)

Osteoporosis - secondary prevention including strontium ranelate: background to the reconsideration of strontium ranelate (PDF 27 KB)

Osteoporosis - secondary prevention including strontium ranelate: history of the appraisal development (PDF 31 KB)

Osteoporosis - secondary prevention including strontium ranelate: guidance for the Committee on the reconsideration of strontium ranelate (PDF 32 KB)

Osteoporosis - secondary prevention including strontium ranelate: final matrix of Consultees and Commentators for the reconsideration of strontium ranelate (PDF 35 KB)

Osteoporosis - secondary prevention including strontium ranelate: NICE Statement of Reasons (PDF 37 KB)

Osteoporosis - secondary prevention including strontium ranelate: Servier response to the NICE Statement of Reasons and clarification on Servier response

Osteoporosis - secondary prevention including strontium ranelate: Servier response to the NICE Statement of Reasons (PDF 104 KB)

Osteoporosis - secondary prevention including strontium ranelate: appendices A and B to Servier response (PDF 418 KB)

Osteoporosis - secondary prevention including strontium ranelate: NICE request to Servier for clarification of their response (PDF 60 KB)

Osteoporosis - secondary prevention including strontium ranelate: Servier response to NICE's request for clarification (PDF 92 KB)

Osteoporosis - secondary prevention including strontium ranelate: appendix 1 of Servier response to clarification request (PDF 2.35 MB)

Osteoporosis - secondary prevention including strontium ranelate: Decision Support Unit (DSU) report

Osteoporosis - secondary prevention including strontium ranelate: DSU specification (PDF 56 KB)

Osteoporosis - secondary prevention including strontium ranelate: DSU report (PDF 71 KB)

Osteoporosis - secondary prevention including strontium ranelate: Servier response to DSU report (PDF 37 KB)

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination 2 information

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination 2 (PDF 324 KB)

Osteoporosis - secondary prevention including strontium ranelate: overview (PDF 161 KB)

Osteoporosis - secondary prevention including strontium ranelate: court judgment and order

Osteoporosis - secondary prevention including strontium ranelate: court judgment (PDF 313 KB)

Osteoporosis - secondary prevention including strontium ranelate: court order (PDF 237 KB)

Osteoporosis - secondary prevention including strontium ranelate: comments on the economic model

Bone Research Society (PDF 228 KB)

National Osteoporosis Society (PDF 45 KB)

Servier (PDF 92 KB)

Society for Endocrinology (PDF 10 KB)

Decision Support Unit report

DSU specification (PDF 29 KB)

DSU report (PDF 692 KB)

Comments on the Decision Support Unit report

Bone Research Society (PDF 22 KB)

British Society for Rheumatology (PDF 34 KB)

Department of Health (PDF 11 KB)

National Osteoporosis Society (PDF 73 KB)

Servier (PDF 276 KB)

Osteoporosis - primary and secondary prevention: appeal announcement information

Servier Laboratories Ltd

Appeals received (PDF 155 KB)

Initial scrutiny letter (PDF 103 KB)

Response to initial scrutiny letter (PDF 59 KB)

Scrutiny letter (PDF 49 KB)

Response to scrutiny letter (PDF 98 KB)

Final scrutiny letter (PDF 58 KB)

Osteoporosis - primary and secondary prevention: notice of appeal information

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination information

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination (PDF 313 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 507 KB)

Addendum to the Assessment Report information

Addendum to the Assessment Report (PDF 56 KB)

Consultee and commentator comments on the ACD

The Alliance for Better Bone Health (Proctor & Gamble in association with Aventis) (PDF 247 KB)

Bone Research Society (PDF 96 KB)

British Society for Rheumatology (PDF 120 KB)

Department of Health (PDF 12 KB)

Eli Lilly and Company (PDF 21 KB)

National Osteoporosis Society (PDF 50 KB)

NHS Quality Improvement Scotland (PDF 111 KB)

Novartis (PDF 28 KB)

Roche (PDF 27 KB)

Royal College of Nursing (PDF 23 KB)

Royal College of Pathologists (PDF 20 KB)

Royal College of Physicians (PDF 20 KB)

Servier (PDF 667 KB)

Society for Endocrinology (PDF 146 KB)

Southwark PCT (PDF 13 KB)

Comments from the NICE Guideline Development Group (PDF 143 KB)

Expert comments on the ACD

Compston (PDF 18 KB)

Francis (PDF 28 KB)

Selby (PDF 186 KB)

Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation (March 2008)

Osteoporosis - secondary prevention including strontium ranelate: Appraisal consultation document (March 2008) information

Evaluation report (March 2008)

Comments or observations from consultees and commentators

Society for Endocrinology (PDF 74 KB)

Servier (PDF 173 KB)

National Osteoporosis Society (PDF 93 KB)

Guideline Development Group (PDF 55 KB)

Letter from NICE regarding additional comments (PDF 24 KB)

Critique of evidence put forward by Servier suggesting an association between acid-suppressive medication and fracture risk (PDF 93 KB)

Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the cost-effectiveness of risedronate and strontium ranelate in those people who would be treated with generic alendronate (PDF 204 KB)

Specifications issued to the Decision Support Unit (PDF 77 KB)

Osteoporosis - secondary prevention including strontium ranelate: decision support unit specification (PDF 26 KB)

Osteoporosis - secondary prevention including strontium ranelate: appraisal update to consultees and commentators (PDF 24 KB)

Osteoporosis - secondary prevention including strontium ranelate: appeal panel decision letter (PDF 109 KB)

Osteoporosis - secondary prevention including strontium ranelate: appeal documents

Alliance for Better Bone Health and sanofi-aventis

ABBH response to scrutiny letter

sanofi-aventis - July 2007 (PDF 1.22 MB)

sanofi-aventis - September 2007 (PDF 130 KB)

Appeals received

Alliance for Better Bone Health - secondary prevention (PDF 1.31 MB)

Alliance for Better Bone Health - primary prevention (PDF 1.22 MB)

Final scrutiny letter (PDF 19 KB)

Initial scrutiny letter (PDF 57 KB)

Servier

Final scrutiny letter (PDF 21 KB)

Servier response to scrutiny letter (PDF 218 KB)

Initial scrutiny letter (PDF 24 KB)

Appeals received (PDF 201 KB)

NOS/SfE/BRS/BSR

Final scrutiny letter (PDF 101 KB)

NOS response to scrutiny letter (PDF 375 KB)

Initial scrutiny letter (PDF 115 KB)

Appeals received (PDF 733 KB)

Osteoporosis - secondary prevention including strontium ranelate: appeal against the clinical and cost effectiveness of technologies for the primary and secondary prevention of osteoporosis information

Osteoporosis - secondary prevention including strontium ranelate: details of appeal announced to consultees and commentators information

Appeal against the clinical and cost effectiveness of technologies for the primary and secondary prevention of osteoporosis information

Osteoporosis - secondary prevention including strontium ranelate: appeal letter to consultees and commentators information

Osteoporosis - secondary prevention including strontium ranelate: letter to consultees and commentators about the link of FAD to technology appraisal TA87 (PDF 37 KB)

Osteoporosis - primary and secondary prevention: final appraisal determination information

Osteoporosis - primary prevention (final appraisal determination) (PDF 161 KB)

Response to consultee, commentator and public comments on the 2007 Appraisal Consultation Document (ACD) (Primary Prevention) (PDF 620 KB)

Osteoporosis - secondary prevention (final appraisal determination) (PDF 172 KB)

Response to consultee, commentator and public comments on the 2007 Appraisal Consultation Document (ACD) (Secondary Prevention) (PDF 286 KB)

Responses to summarised comments from consultees, commentators and the public on the 2005 Appraisal Consultation Document (ACD) (PDF 130 KB)

Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation (February 2007)

Osteoporosis - primary prevention: Appraisal consultation document information

Evaluation report (February 2007)

Response from Committee to GDG comments on ACDs (September 2006) for Osteoporosis - Primary and Secondary (PDF 260 KB)

Additional Analyses - Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, risedronate, strontium ranelate, raloxifene and teriparatide following corrections to the methodology associated with lower efficacy in some risk factors (PDF 250 KB)

Outcome from November 2006 Committee Meeting discussion on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (PDF 996 KB)

Table of Consultee and Commentator Comments on ACDs (September 2006) for Osteoporosis - Primary and the Institute's response (PDF 909 KB)

Table of Non-Consultee and Commentator Comments on ACD (2006) for Osteoporosis - Primary (PDF 309 KB)

Table of Consultee and Commentator Comments on ACDs (September 2006) for Osteoporosis - Secondary and the Institute's response (PDF 206 KB)

Table of Non-Consultee and Commentator Comments on ACD (2006) for Osteoporosis - Secondary (PDF 81 KB)

Comments received from non- consultees and commentators and the Institute's response on the ACD (2006) - Primary (PDF 391 KB)

Comments received from non-consultees and commentators and the Institute's response on the ACD (2006) - Secondary (PDF 101 KB)

Osteoporosis - primary prevention: Appraisal consultation document (September 2006 - for reference only) information

Osteoporosis - primary prevention: Memo to consultees and commentators information

Osteoporosis - secondary prevention including strontium ranelate: letter sent to consultees and commentators regarding the delay to the release of the FAD (PDF 26 KB)

Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation (September 2006)

Appraisal Consultation Document: Osteoporosis - secondary prevention including strontium ranelate (Sept 05 - reference only) (PDF 178 KB)

Evaluation report (September 2006) information

Osteoporosis - secondary prevention including strontium ranelate: decision support unit project specification letter (PDF 16 KB)

Osteoporosis - secondary prevention including strontium ranelate: decision support unit project specification (PDF 34 KB)

Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation (September 2005)

Appraisal Consultation Document: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women information

Osteoporosis - primary and secondary prevention: Evaluation report (September 2005)

Assessment report and addendum

Assessment report (PDF 599 KB)

Addendum to the Assessment report (PDF 150 KB)

Corrections and further analysis on strontium ranelate Assessment Report by Assessment Group (PDF 37 KB)

Cost effectiveness data for figures 1-14 in the addendum to the Assessment Report (PDF 37 KB)

Consultee and commentator comments on the assessment report

Alliance for Better Bone Health (addendum to AR) (1) (PDF 306 KB)

Alliance for Better Bone Health (2) (PDF 53 KB)

Arthritis and Musculoskeletal Alliance (PDF 23 KB)

British Menopause Society (PDF 12 KB)

British Society for Rheumatology (PDF 32 KB)

Community Practitioners and Health Visitors Association (PDF 12 KB)

Eli Lilly and Company (PDF 26 KB)

Guidelines Development Group (PDF 18 KB)

Merck Sharp and Dohme (PDF 47 KB)

National Osteoporosis Society (PDF 17 KB)

NHS Quality Improvement Scotland (PDF 17 KB)

Novartis Pharmaceuticals UK (PDF 43 KB)

Royal College of General Practitioners (1) (PDF 14 KB)

Royal College of General Practitioners (2) (PDF 15 KB)

Royal College of Pathologists (PDF 24 KB)

Royal College of Physicians (PDF 42 KB)

Royal Pharmaceutical Society of Great Britain (PDF 31 KB)

Servier Laboratories (PDF 88 KB)

Society for Endocrinology (PDF 15 KB)

Royal College of Nursing (PDF 17 KB)

Non-manufacturer submissions

British Society for Rheumatology (PDF 36 KB)

National Osteoporosis Society (PDF 80 KB)

Primary Care Rheumatology Society (PDF 34 KB)

Royal College of Pathologists (PDF 13 KB)

The Society for Endocrinology (PDF 28 KB)

Servier (PDF 34 KB)

Expert written personal statements

Compston and Selby (PDF 24 KB)

Francis (PDF 16 KB)

Moniz (PDF 20 KB)

Appraisal Consultation Document: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women information

Osteoporosis - secondary prevention including strontium ranelate:: letter to consultees and commentators regarding ongoing development (PDF 122 KB)

Osteoporosis - secondary prevention including strontium ranelate: final protocol (PDF 167 KB)

Osteoporosis - secondary prevention including strontium ranelate: final scope (PDF 28 KB)

Osteoporosis - secondary prevention including strontium ranelate: draft scope (PDF 79 KB)

Osteoporosis - secondary prevention including strontium ranelate: response to comments on the draft scope (PDF 48 KB)

Osteoporosis - secondary prevention including strontium ranelate: response to comments on the provisional matrix (PDF 25 KB)

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information